Watch OBIO. Know when insiders buy.
One email the day a filing lands. Free.
Work order
53
WATCH · insiders 52, shorts 54
Insiders, 90 days
−$63K
net selling · 1 buy, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $284.9MP/E —DIV YIELD —FCF YIELD -20.74%REV TTM $32M +986.1%NET INCOME −$59MNET CASH $5.5M52W 2.35 – 5.66NEXT EARNINGS Nov 5 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $88K | −89.5% | 71.6% | −$22.4M | −$23.8M | — | -0.38 | −$19.3M | $254K | −$19.6M | Aug 10 |
| Q1 2026 · Mar 31 | $110K | −87.3% | 70.9% | −$22.1M | −$20.7M | — | -0.33 | −$22.2M | $184K | −$22.4M | Aug 10 |
| Q4 2025 · Dec 31derived | $30.9M | +12120.2% | 99.8% | $6.8M | $6.2M | — | 0.26 | −$2.3M | $33K | −$2.3M | Mar 12 |
| Q3 2025 · Sep 30 | $861K | −12.8% | 94.3% | −$20.3M | −$20.8M | — | -0.40 | −$14.6M | $310K | −$14.9M | Nov 10 |
| Q2 2025 · Jun 30 | $836K | +7.5% | 94.5% | −$19.3M | −$19.4M | — | -0.50 | −$15.5M | $34K | −$15.6M | Aug 10 |
| Q1 2025 · Mar 31 | $868K | +40.0% | 94.9% | −$18.9M | −$18.8M | — | -0.49 | −$16.6M | $112K | −$16.7M | Aug 10 |
| Q4 2024 · Dec 31derived | $253K | −3.4% | 77.1% | −$16.7M | −$16.2M | — | -0.43 | −$13.5M | $106K | −$13.6M | Mar 12 |
| Q3 2024 · Sep 30 | $987K | +135.6% | 93.1% | −$16.3M | −$15.4M | — | -0.41 | −$13.7M | $68K | −$13.8M | Nov 10 |
| Q2 2024 · Jun 30 | $778K | — | 94.3% | −$16.9M | −$16M | — | -0.45 | −$10.2M | $107K | −$10.3M | Nov 10 |
| Q1 2024 · Mar 31 | $620K | — | 94.5% | −$14.4M | −$13.5M | — | -0.38 | −$13.1M | $8K | −$13.1M | Nov 10 |
| Q4 2023 · Dec 31derived | $262K | — | 82.1% | −$12.5M | −$12.8M | — | -0.37 | −$11M | −$3K | −$11M | Mar 31 |
| Q3 2023 · Sep 30 | $419K | — | 90.2% | −$14.5M | −$13.3M | — | -0.38 | −$10.3M | $19K | −$10.3M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $33.5M | 99.4% | −$51.8M | −$52.7M | -157.4% | -1.11 | −$49M | $489K | −$49.5M | — | — |
| FY2024 · to Dec 31 | $2.6M | 92.3% | −$64.3M | −$61M | -2313.3% | -1.66 | −$50.6M | $289K | −$50.8M | — | — |
| FY2023 · to Dec 31 | $2.8M | 93.3% | −$51.5M | −$49.1M | -1779.7% | -1.48 | −$46.1M | $78K | −$46.2M | — | — |
| FY2022 · to Dec 31 | $3.5M | 94.0% | −$32.7M | −$33.6M | -951.3% | -2.24 | −$29.3M | $591K | −$29.9M | — | — |
| FY2021 · to Dec 31 | — | — | −$395K | −$379K | — | -0.02 | −$272K | — | — | — | — |
Every number comes from Orchestra BioMed Holdings, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.